HealthEquity (HQY) Stock Forecast & Price Target

HealthEquity is benefiting from strong operational execution, with F2Q:27 revenue of $350.7M and adjusted EBITDA of $167M both topping estimates while EBITDA margin reached a company-high ~48%, showing meaningful leverage in its recurring platform model. It is also gaining share, as HSA members rose 8% year over year, new HSA sales increased 24%, custodial assets grew 14%, and renewals are tracking well above 90%, reinforcing the durability of its customer base. The long-term outlook remains constructive because higher-deductible plan adoption, expanded HSA eligibility, and higher custodial yields support a larger addressable market, while AI, automation, and the expanding marketplace should continue to lift margins and deepen engagement.

HealthEquity is facing a fundamentally challenged outlook because its HSA-led model is exposed to lower interest rates, weaker investment returns, and a recessionary labor backdrop that could slow account and balance growth if unemployment rises above 5%. The business also operates in a young, highly competitive industry with meaningful regulatory uncertainty, while alternative payment methods and healthcare-rule changes could pressure utilization and margins; the downside case assumes 5% topline growth and 200bps of margin contraction in 2027. In addition, the company’s most material risk is cybersecurity, as a class action lawsuit and millions in fraud-related costs underscore the earnings and reputational damage that data breaches can create.